Drugs / Base-edited T lymphocyte cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06959771 | Jul 2025 → Oct 2027 expected | hyper-IgM syndrome type 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Base-edited T lymphocyte cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06959771 ↗ |